Surprisingly, there were no significant clinical differences between EBV positive DLBCLs and EBV negative DLBCL cohort in terms of age, gender, subtype, revised International Prognostic Index (R-IPI), Eastern Cooperative Oncology Group (ECOG) score, Ann Arbor stage, B symptoms, bone marrow involvement, serologic LDH and B2M, chemotherapeutic regimen and double/triple gene alteration (C-MYC, BCL2 and/or BCL6) detected by FISH and/IHC. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.